Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors

American Journal of Epidemiology

Volumn 167, Issue 6, 2008, Pages 743-750

  Guiltinan, Anne M ^a   Kaidarova, Zhanna ^a   Custer, Brian ^a   Orland, Jennie ^a,b   Strollo, Angela ^c   Cyrus, Sherri ^d   Busch, Michael P ^a,b   Murphy, Edward L ^a,b,e  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Blood Systems Incorporated   (United States)

^d Blood Systems Laboratories   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Blood donors; Hepacivirus; Liver diseases; Mortality

Indexed keywords

ALCOHOL;

BLOOD; CANCER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DRUG USER; EPIDEMIOLOGY; ETHANOL; HEALTH STATUS; HEPATITIS; LIFESTYLE; MORBIDITY; MORTALITY; SURVIVAL; VIRAL DISEASE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ATHEROSCLEROSIS; BLOOD DONOR; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ALCOHOL INTERACTION; FEMALE; FOLLOW UP; HEART DISEASE; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; SERODIAGNOSIS; SUICIDE;

ADULT; AGED; BLOOD DONORS; CALIFORNIA; FEMALE; HEART DISEASES; HEPATITIS C; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDIES; RISK; VITAL STATISTICS;

HEPACIVIRUS; HEPATITIS C VIRUS;

EID: 41149142905     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm370     Document Type: Article

References (42)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
2. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000;31:756-62.
3. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-905.
4. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
5. Briggs ME, Baker C, Hall R, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001;34:1200-5.
6. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
7. Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993;119:110-15.
8. Gordon SC, Elloway RS, Long JC, et al. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43.
9. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
10. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
11. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
12. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(suppl):2S-10S.
13. Fellgi I, Sunter A. A theory for record linkage. J Am Stat Assoc 1969;64:1183-210.
14. Rogot E, Sorlie P, Johnson N. Probabilistic methods in matching census samples to the National Death Index. J Chronic Dis 1986;39:719-34.
15. National Center for Health Statistics. GMWK12. Death rates for 358 selected causes, by 10-year age groups, race, and sex: United States, 1999-2004. Hyattsville, MD: National Center for Health Statistics, 2005. (www.cdc.gov/nchs/datawh/statab/unpubd/mortabs/gmwk12_10.htm).
16. Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002;2:443-7.
17. Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004;23:277-83.
18. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359:133-5.
19. Vassalle C, Masini S, Bianchi F, et al. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004;90:565-6.
20. Harris HE, Ramsay ME, Andrews NJ. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect 2006;134:472-7.
21. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-63.
22. Lumbreras B, Jarrin I, del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006;20:111-16.
23. Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000;32:582-7.
24. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
25. Murphy EL, Bryzman S, Williams AE, et al. Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA 1996;275:995-1000.
26. Delage G, Infante-Rivard C, Chiavetta JA, et al. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology 1999;116:893-9.
27. Brandao AB, Fuchs SC. Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study. (e-publication). BMC Gastroenterol 2002;2:18.
28. Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997;277:967-72.
29. el-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123:476-82.
30. Schoener EP, Hopper JA, Pierre JD. Injection drug use in North America. Infect Dis Clin North Am 2002;16:535-51, vii.
31. Nguyen HA, Miller AI, Dieperink E, et al. Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002;97:1813-20.
32. Lai S, Lai H, Meng Q, et al. Effect of cocaine use on coronary calcium among black adults in Baltimore, Maryland. Am J Cardiol 2002;90:326-8.
33. Younossi ZM, Braun WE, Protiva DA, et al. Chronic viral hepatitis in renal transplant recipients with allografts functioning for more than 20 years. Transplantation 1999;67:272-5.
34. Volzke H, Schwahn C, Wolff B, et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004;174:99-103.
35. Arcari CM, Nelson KE, Netski DM, et al. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006;43:e53-6.
36. Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001;103:1064-70.
37. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005;5:227-36.
38. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003;325:135-48.
39. Koike K. Steatosis in chronic hepatitis C: fuel for over-production of oxidative stress? J Gastroenterol 2005;40:664-5.
40. Cowper DC, Kubal JD, Maynard C, et al. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002;12:462-8.
41. Cantwell MF, McKenna MT, McCray E, et al. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998;157:1016-20.
42. Fiscella K, Franks P. Impact of patient socioeconomic status on physician profiles: a comparison of census-derived and individual measures. Med Care 2001;39:8-14.